Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

, RHHBY

Roche

$30.83

0.13 (0.42%)

08:33
10/06/16
10/06
08:33
10/06/16
08:33

Kite Pharma initiates phase 1b/2 combination study for KTE-C19, atezolizumab

Kite Pharma (KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma. PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group (RHHBY), to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab. The first ZUMA-6 patient was enrolled at the end of September 2016.

KITE

Kite Pharma

$56.41

1.57 (2.86%)

RHHBY

Roche

$30.83

0.13 (0.42%)

  • 07

    Oct

  • 18

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

KITE Kite Pharma
$56.41

1.57 (2.86%)

09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Kite Pharma data positive, says RBC Capital
RBC Capital analyst Michael Yee says that Kite reported positive Phase II data for its KTE-C19 drug in DLBCL with a 47% complete response rate which beat expectations. The analyst says that the complete response rate "is very supportive of FDA approval." He keeps an Outperform rating on the shares.
09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
RHHBY Roche
$30.83

0.13 (0.42%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:09
12/04/16
12/04
15:09
12/04/16
15:09
Conference/Events
Juno Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$18.90

-0.3 (-1.56%)

15:04
12/04/16
12/04
15:04
12/04/16
15:04
Hot Stocks
Atara Biotherapeutics reports presentation of Phase 2 CMV-CTL data »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$45.32

-0.41 (-0.90%)

15:03
12/04/16
12/04
15:03
12/04/16
15:03
Conference/Events
Johnson Controls to hold a meeting »

Strategic Review &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$297.19

1.41 (0.48%)

14:59
12/04/16
12/04
14:59
12/04/16
14:59
Hot Stocks
Biogen reports data presentations on hemophilia treatments Eloctate, Alprolix »

Biogen and Swedish Orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

14:58
12/04/16
12/04
14:58
12/04/16
14:58
Conference/Events
Genmab to hold data review meeting »

Management discusses data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

, GOOG

Alphabet

$750.50

2.58 (0.34%)

14:53
12/04/16
12/04
14:53
12/04/16
14:53
Hot Stocks
Alphabet subsidiary Verily launches utensil product »

Alphabet subsidiary…

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

KYN

Kayne Anderson

$19.52

0.07 (0.36%)

14:48
12/04/16
12/04
14:48
12/04/16
14:48
Hot Stocks
Kayne Anderson reports net assets $2.2B as of November 30 »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KED

Kayne Anderson

$19.29

0.03 (0.16%)

14:47
12/04/16
12/04
14:47
12/04/16
14:47
Hot Stocks
Kayne Anderson reports net assets $205M as of November 30 »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$36.23

-0.05 (-0.14%)

, BURBY

Burberry

$18.08

0.265 (1.49%)

14:37
12/04/16
12/04
14:37
12/04/16
14:37
Periodicals
Burberry rejected multiple approaches from Coach, FT says »

Burberry (BURBY) rejected…

COH

Coach

$36.23

-0.05 (-0.14%)

BURBY

Burberry

$18.08

0.265 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.22

0.03 (1.37%)

, AMP

Ameriprise

$113.47

-1.57 (-1.36%)

14:31
12/04/16
12/04
14:31
12/04/16
14:31
Periodicals
UniCredit to sell asset manager to Amundi for over EUR 3B, FT says »

UniCredit (UNCFF) is set…

UNCFF

UniCredit

$2.22

0.03 (1.37%)

AMP

Ameriprise

$113.47

-1.57 (-1.36%)

FIG

Fortress

$5.10

-0.1 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RXN

Rexnord

$20.27

-0.72 (-3.43%)

14:09
12/04/16
12/04
14:09
12/04/16
14:09
Hot Stocks
Trump targets Rexnord over Mexico relocation plans, says 'no more' »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.61

-0.27 (-0.69%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

13:57
12/04/16
12/04
13:57
12/04/16
13:57
Periodicals
DirecTV NOW unlikely to make money, Barron's says »

AT&T's (T)…

T

AT&T

$38.61

-0.27 (-0.69%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

ARCH

Arch Coal

$79.32

1.6 (2.06%)

13:27
12/04/16
12/04
13:27
12/04/16
13:27
Periodicals
Arch Coal could gain 75%, Barron's says »

Arch Coal, which emerged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$101.50

-1.2 (-1.17%)

13:12
12/04/16
12/04
13:12
12/04/16
13:12
Periodicals
Deere could keep climbing, Barron's says »

Deere stock recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$9.81

0.28 (2.94%)

, GME

GameStop

$24.27

-0.37 (-1.50%)

12:57
12/04/16
12/04
12:57
12/04/16
12:57
Periodicals
Corporate tax cut can't save all retailers, Barron's says »

Though President-elect…

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

12:40
12/04/16
12/04
12:40
12/04/16
12:40
Periodicals
Callaway Golf investors should take profits, Barron's says »

It "looks like a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVC

Entravision

12:36
12/04/16
12/04
12:36
12/04/16
12:36
Periodicals
Entravision shares could reach $9, Barron's says »

Hispanic-focused…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GOOG

Alphabet

$750.50

2.58 (0.34%)

, GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

12:26
12/04/16
12/04
12:26
12/04/16
12:26
Periodicals
Barron's picks top ten stocks for 2017 »

Selecting its ten…

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AAPL

Apple

$109.90

0.41 (0.37%)

C

Citi

$56.02

-1.25 (-2.18%)

DAL

Delta Air Lines

$48.31

0.54 (1.13%)

DTEGY

Deutsche Telekom

$15.65

0.14 (0.90%)

MRK

Merck

$61.13

0.37 (0.61%)

NVS

Novartis

$68.17

0.42 (0.62%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

UL

Unilever; also tag UN

$39.67

0.5 (1.28%)

UN

Unilever; also tag UL

$39.47

0.35 (0.89%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 15

    Jan

  • 26

    Jan

  • 08

    Mar

  • 13

    Mar

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.